Protocol for CRISPR-Cas9 genome editing of a swine cell line via electroporation.

Patricia Kiesler, Stella S Lee, Alexis L Norris, Mayumi F Miller, Carlo J Mercado, Adam L Moyer, Samantha Maragh

Abstract read

In one paragraph

Article in STAR protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patricia KieslerBiosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA. Electronic address: patricia.kiesler@nist.gov.

Stella S LeeCenter for Veterinary Medicine, Office of New Animal Drug Evaluation, US Food and Drug Administration, Rockville, MD 20855, USA.

Alexis L NorrisCenter for Veterinary Medicine, Office of New Animal Drug Evaluation, US Food and Drug Administration, Rockville, MD 20855, USA.

Mayumi F MillerCenter for Veterinary Medicine, Office of Applied Science, US Food and Drug Administration, Laurel, MD 20708, USA.

Carlo J MercadoCenter for Veterinary Medicine, Office of New Animal Drug Evaluation, US Food and Drug Administration, Rockville, MD 20855, USA.

Adam L MoyerCenter for Veterinary Medicine, Office of New Animal Drug Evaluation, US Food and Drug Administration, Rockville, MD 20855, USA.

Samantha MaraghBiosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA. Electronic address: samantha.maragh@nist.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genome editing technology is being used in animals for a variety of purposes, including improvement of animal and public health outcomes. Characterization of genome editing reagents and anticipated genomic alterations is an essential step toward the development of an edited animal. Here, we present a protocol for genome editing in the swine testicular (ST) cell line. We describe steps for evaluating CRISPR-Cas9 complex functionality in vitro, delivering editing molecules into cells by transfection, and assessing target editing via Sanger sequencing.

Indexed as

CRISPR-Cas SystemsElectroporationGene EditingAnimalsCell LineMaleSwineTestisTransfectionBiotechnology and bioengineeringCell-based AssaysCRISPR

Identifiers

PMID39392744

DOI10.1016/j.xpro.2024.103385

PMCPMC11735999

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.